Table 1

Characteristics of NeuroEDIC participants at DCCT baseline, DCCT closeout, and EDIC years 13–14

CharacteristicDCCT baselineDCCT closeoutEDIC years 13–14
Age (years)
    INT (n = 603)27 ± 7*34 ± 7*48 ± 7*
    CONV (n = 583)27 ± 733 ± 747 ± 7
Female
    INT294 (49)294 (49)294 (49)
    CONV268 (46)268 (46)268 (46)
Height (cm)
    INT171 ± 10172 ± 10171 ± 9
    CONV172 ± 10172 ± 10173 ± 10
Weight (kg)
    INT68 ± 1178 ± 1484 ± 17
    CONV70 ± 1375 ± 1384 ± 17
BMI (kg/m2)
    INT23 ± 327 ± 429 ± 5
    CONV24 ± 325 ± 328 ± 5
BMI >30 (kg/m2)
    INT7 ± 1115 ± 20202 ± 34
    CONV10 ± 227 ± 5173 ± 30
Diabetes duration (years)
    INT6 ± 412 ± 526 ± 5
    CONV6 ± 412 ± 526 ± 5
A1C (%)
    INT9.1 ± 1.67.3 ± 1.07.8 ± 1.2
    CONV8.9 ± 1.69.1 ± 1.57.8 ± 1.2
Systolic blood pressure (mmHg)
    INT113 ± 12116 ± 11121 ± 14
    CONV115 ± 12116 ± 12120 ± 14
Diastolic blood pressure (mmHg)
    INT72 ± 975 ± 974 ± 9
    CONV73 ± 974 ± 973 ± 9
Total cholesterol (mg/dl)
    INT177 ± 33180 ± 31176 ± 36
    CONV174 ± 33183 ± 36173 ± 35
LDL cholesterol (mg/dl)
    INT111 ± 29112 ± 27103 ± 30
    CONV108 ± 29114 ± 31100 ± 31
Current smoker
    INT125 (21)134 (22)87 (14)
    CONV111 (19)119 (20)79 (14)
Any ACE inhibitors or angiotensin receptor II blockers
    INT290 (48)
    CONV301 (52)
Medication for neuropathic pain in hands/feet
    INT41 (7)
    CONV35 (6)
  • Data are means ± SD or n (%).

  • *P < 0.05 former intensive treatment group (INT) vs. former conventional treatment group (CONV).

  • P < 0.01 INT vs. CONV.

  • ‡Data on medication use was not collected during the DCCT.